Showing results (31-40 of 83) with videos related to
Sort By:
Pageof 9
Oncotarget|April 16, 2014
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutationFrancesco Sabbatino, Yangyang Wang, Xinhui Wang, et al.British Journal of Cancer|July 24, 2024
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancerNeil H Segal, Jeanne Tie, Scott Kopetz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2022
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung CancerRoy S Herbst, Margarita Majem, Fabrice Barlesi, et al.JAMA Network Open|July 15, 2025
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical TrialCharu Aggarwal, Alex Martinez-Marti, Margarita Majem, et al.Cancer Cell|March 16, 2016
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma TherapyMichael P Smith, Holly Brunton, Emily J Rowling, et al.Oncoimmunology|May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanomaMeghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.Oncoimmunology|December 7, 2017
Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumabAlexandre Reuben, Mariana Petaccia de Macedo, Jennifer McQuade, et al.JCI Insight|February 8, 2022
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLCEric Tu, Kelly McGlinchey, Jixin Wang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.The Journal of Clinical Investigation|February 24, 2015
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaLawrence N Kwong, Genevieve M Boland, Dennie T Frederick, et al.Pageof 9